These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

765 related articles for article (PubMed ID: 21872624)

  • 1. Transport of drugs across the blood-brain barrier by nanoparticles.
    Wohlfart S; Gelperina S; Kreuter J
    J Control Release; 2012 Jul; 161(2):264-73. PubMed ID: 21872624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?
    Kreuter J
    Adv Drug Deliv Rev; 2014 May; 71():2-14. PubMed ID: 23981489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier.
    Wohlfart S; Khalansky AS; Gelperina S; Begley D; Kreuter J
    J Control Release; 2011 Aug; 154(1):103-7. PubMed ID: 21616104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier.
    Andrieux K; Couvreur P
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(5):463-74. PubMed ID: 20049811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles.
    Voigt N; Henrich-Noack P; Kockentiedt S; Hintz W; Tomas J; Sabel BA
    Eur J Pharm Biopharm; 2014 May; 87(1):19-29. PubMed ID: 24607790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug delivery to the CNS and polymeric nanoparticulate carriers.
    Costantino L
    Future Med Chem; 2010 Nov; 2(11):1681-701. PubMed ID: 21428839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric nanoparticles for the drug delivery to the central nervous system.
    Tosi G; Costantino L; Ruozi B; Forni F; Vandelli MA
    Expert Opin Drug Deliv; 2008 Feb; 5(2):155-74. PubMed ID: 18248316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nano-enabled delivery systems across the blood-brain barrier.
    Hwang SR; Kim K
    Arch Pharm Res; 2014 Jan; 37(1):24-30. PubMed ID: 24170511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
    Juillerat-Jeanneret L
    Drug Discov Today; 2008 Dec; 13(23-24):1099-106. PubMed ID: 18848640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nano carriers for drug transport across the blood-brain barrier.
    Li X; Tsibouklis J; Weng T; Zhang B; Yin G; Feng G; Cui Y; Savina IN; Mikhalovska LI; Sandeman SR; Howel CA; Mikhalovsky SV
    J Drug Target; 2017 Jan; 25(1):17-28. PubMed ID: 27126681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chapter 3 - Colloidal systems for CNS drug delivery.
    Costantino L; Tosi G; Ruozi B; Bondioli L; Vandelli MA; Forni F
    Prog Brain Res; 2009; 180():35-69. PubMed ID: 20302828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
    Kurakhmaeva KB; Djindjikhashvili IA; Petrov VE; Balabanyan VU; Voronina TA; Trofimov SS; Kreuter J; Gelperina S; Begley D; Alyautdin RN
    J Drug Target; 2009 Sep; 17(8):564-74. PubMed ID: 19694610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain iron homeostasis.
    Moos T
    Dan Med Bull; 2002 Nov; 49(4):279-301. PubMed ID: 12553165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internal benchmarking of a human blood-brain barrier cell model for screening of nanoparticle uptake and transcytosis.
    Ragnaill MN; Brown M; Ye D; Bramini M; Callanan S; Lynch I; Dawson KA
    Eur J Pharm Biopharm; 2011 Apr; 77(3):360-7. PubMed ID: 21236340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HI 6 human serum albumin nanoparticles--development and transport over an in vitro blood-brain barrier model.
    Dadparvar M; Wagner S; Wien S; Kufleitner J; Worek F; von Briesen H; Kreuter J
    Toxicol Lett; 2011 Sep; 206(1):60-6. PubMed ID: 21726608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution.
    Tosi G; Vergoni AV; Ruozi B; Bondioli L; Badiali L; Rivasi F; Costantino L; Forni F; Vandelli MA
    J Control Release; 2010 Jul; 145(1):49-57. PubMed ID: 20338201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.
    Tosi G; Costantino L; Rivasi F; Ruozi B; Leo E; Vergoni AV; Tacchi R; Bertolini A; Vandelli MA; Forni F
    J Control Release; 2007 Sep; 122(1):1-9. PubMed ID: 17651855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.
    Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA
    Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to overcome the barrier: use of nanoparticles as carriers and modulators of barrier properties.
    Rempe R; Cramer S; Qiao R; Galla HJ
    Cell Tissue Res; 2014 Mar; 355(3):717-26. PubMed ID: 24585360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanotechnological advances for the delivery of CNS therapeutics.
    Wong HL; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.